Biosimilars Forum Sees Lessons Being Learned From US Humira Experience

The low uptake seen for Humira (adalimumab) biosimilars in the first year of US competition has focused people’s minds on the weaknesses of the country’s biosimilars framework, Biosimilars Forum executive director Julie Reed has told Generics Bulletin in an exclusive interview.

But despite obstacles to uptake for biosimilars in the US, the industry association remains optimistic that policy-makers and stakeholders will look at the roadblocks and address some of the more suboptimal